News Release(2013)

December 24, 2013

Kissei Announces Licensing Agreement with Pfizer Inc. for KUX-1151, a Novel Investigational Therapy for Gout and Hyperuricemia

October 17, 2013

Kissei and Kyorin announce the initiation of a Phase I clinical trial of KEA-0447/KRP-EPA605 for the treatment of overactive bladder

September 30, 2013

Conclusion of an Agreement about Long-Acting Erythropoiesis Stimulating Agent.

September 13, 2013

Approval of Partial Changes of Indication of Glufast® in Japan

January 30, 2013

New Drug Application submitted for "Dexrazoxane" for the Treatment of Anthracycline Extravasation in Japan